Compare Gilead Sciences, Inc. (GILD) vs T1 Energy Inc. Common Stock (TE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs T1 Energy Inc. Common Stock — how do they compare? Gilead Sciences, Inc. trades at $158.72 (market cap $190.38B), while T1 Energy Inc. Common Stock trades at $2.68 (market cap $868.55M). The key difference: Gilead Sciences, Inc. is far larger — about 219.2× T1 Energy Inc. Common Stock's market cap, and Gilead Sciences, Inc. pays a 2.14% dividend while T1 Energy Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 112 Days and T1 Energy Inc. Common Stock for 0 Days on average.
| GILD | TE | |
|---|---|---|
Market Cap | $190.38B | $868.55M |
Volume | 5,758,183 | 19,771,934 |
Sector | Health | Industrials |
52-Week High | $155.80 | $12.04 |
52-Week Low | $117.85 | $2.72 |
Typical Hold Time | 112 Days | 0 Days |
Enterprise Value | $213.45B | $1.64B |
Dividend Yield | 2.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.92, down 1.67% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $153.13. Recent earnings beat expectations in three consecutive quarters, though Q3 2026 results are pending. The company maintains strong operating cash flow of $10.02B in 2025 and has expanded HIV prevention access through a new PAHO partnership in Latin America.
Investment outlook remains positive with 67% analyst buy ratings and potential upside to price targets, though risks include negative net income margin (-10.64%) projected for 2026 and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, but investors should monitor earnings sustainability and pipeline developments in oncology and HIV therapies.
T1 Energy (TE) trades at $3.16, down 1.56% today, reflecting ongoing investor caution despite a mixed earnings history. The company shows significant revenue growth from $755M in 2025 to $997M in 2026 but remains deeply unprofitable with a -38.49% net margin. Recent news highlights strategic moves toward vertical integration in solar manufacturing and energy storage, including the G2_Austin facility development and new supply agreements, which are central to its growth narrative.
The investment case hinges on execution of vertical integration and policy tailwinds, offering substantial upside to the $8 consensus target, but high execution risk, persistent losses, and regulatory scrutiny present clear dangers. Analyst sentiment is mixed with a Moderate Buy rating, yet the stock's viability depends heavily on future profitability improvements from 2027 onward.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About T1 Energy Inc. Common Stock
T1 Energy Inc. manufactures photovoltaic solar modules and cells in US, operating a solar manufacturing facility in Texas acquired from Trina Solar. The company was formerly known as FREYR Battery before rebranding as T1 Energy in 2025 and changing its NYSE ticker from FREY to TE.
Read more on TE →
